| 摘要 |
<p>1. A process for the preparation of an insulin derivative of the formula I, see diagramm : EP0140084,P8,F1 in which R**1 denotes H or H-Phe, a) R**30 represents the radical of a neutral, naturally occurring L-aminoacid and R**31 represents a physiologically acceptable organic group of basic character, comprising up to 3 alpha-aminoacids in which the terminal carboxyl function is in the free form, or b) R**30 represents the radical of a basic, naturally occurring L-aminoacid and R**31 represents a physiologically acceptable organic group of neutral or basic character, comprising up to 3 alpha-aminoacids in which the terminal carboxyl function is in the free from and which insuline derivative has an isoelectric point above 5.8, which comprises reacting an insulin of the formula I in which R**1 denotes H or H-Phe, R**30 denotes the radical of a genetically codable L-aminoacid and R**31 represents OH or a protective group of the carboxy function, with a peptide of the formula III in which a) R**30 represents the radical of a neutral, naturally occurring L-aminoacid and R**31 represents a physiologically acceptable organic group of basic character, comprising up to 3 alpha-aminoacids in which the terminal carboxyl function is in the free from, or b) R**30 represents the radical of a basic, naturally occurring L-aminoacid and R**31 represents a physiologically acceptable organic group of neutral or basic character, comprising up to 3 alpha-aminoacids in which the terminal carboxyl function is in the free form, in the presence of trypsin-like endopeptidase in water, if appropriate with the addition or a suitable organic solvent at a pH value below the isoelectric point of the insulin, and splitting off any protective groups introduced into the side chains.</p> |
